Close to 'Finish Line,' Novavax Enters Phase 3 Trials for COVID-19 Vaccine
Close to ‘Finish Line,’ Novavax Enters Phase 3 Trials for COVID-19 Vaccine Novavax, which is headquartered in Gaithersburg and has facilities in Rockville, announced it has moved into Phase 3 of its efficacy trial for its COVID-19 vaccine. Prevent-19 is designed to determine the efficacy, safety and immunogenicity of its vaccine. It expects to enroll up to 30,000 volunteers throughout the United States and Mexico, of which two thirds of the participants will receive the active vaccine, according to the company’s news release. Novavax is participating in the federal government’s Projec...